Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Adicet Bio, Inc.

ACETNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:01 PM EDTFiling CIK 1720580Accession 0001776004-26-000003
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-08-05
Issuer
Adicet Bio, Inc.
Issuer CIK
0001720580
Trading symbol
ACET

Reporting owner 1

Name
Klickstein Lloyd
Reporting owner CIK
0001776004
Relationship
Director · Officer
Officer title
Chief Medical Officer
Address
C/O ADICET BIO, INC., 131 DARTMOUTH STREET, FLOOR 3, BOSTON, MA, 02116

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)9.162026-08-05A · Form 418,300A0.00[F1]2036-08-04Common Stock18,30018,300D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.↩ 1

Signature 1

Signed
/s/ Nick Harvey, Attorney-in-Fact
Date
2026-08-07

Company context

Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
  2. 10-Q filingNov 5, 2026
  3. Results of Operations and Financial ConditionNov 5, 2026
  4. SCHEDULE 13G/A - filed by FRANKLIN TEMPLETON INC regarding Adicet Bio, Inc.Oct 28, 2026
  5. Regulation FD Disclosure · Other EventsSep 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.